United States-based Titan Pharmaceuticals Inc (NASDAQ: TTNP) yesterday reported its financial results for the first quarter ended 31 March 2019.

During the first quarter of 2019, the company reported around USD0.9m in revenues, up 46% on the year-ago period.

The firm posted total operating expenses for the first quarter of 2019 at around USD5.2m compared with around USD3.5m in the same period in 2018.

Net loss applicable to common shareholders in the first quarter of 2019 was approximately USD4.5m, or approximately USD0.34 per share, compared with a net loss applicable to common shareholders of approximately USD2.6m, or approximately USD0.74 per share, in the same quarter in 2018.